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A B S T R A C T   
Bone defects arising from fractures or disease represent a significant problem for surgeons to manage and are a 
substantial economic burden on the healthcare economy. Recent advances in the development of biomaterial 
substitutes provides an attractive alternative to the current “gold standard” autologous bone grafting. Despite on- 
going research, we are yet to identify cost effective biocompatible, osteo-inductive factors that stimulate 
controlled, accelerated bone regeneration.We have recently reported that enzymes with peroxidase activity 
possess previously unrecognised roles in extracellular matrix biosynthesis, angiogenesis and osteoclastogenesis, 
which are essential processes in bone remodelling and repair. Here, we report for the first time, that plant- 
derived soybean peroxidase (SBP) possesses pro-osteogenic ability by promoting collagen I biosynthesis and 
matrix mineralization of human osteoblasts in vitro. Mechanistically, SBP regulates osteogenic genes responsible 
for inflammation, extracellular matrix remodelling and ossification, which are necessary for normal bone 
healing. Furthermore, SBP was shown to have osteo-inductive properties, that when combined with commer-
cially available biphasic calcium phosphate (BCP) granules can accelerate bone repair in a critical size long bone 
defect ovine model. Micro-CT analysis showed that SBP when combined with commercially available biphasic 
calcium phosphate (BCP) granules significantly increased bone formation within the defects as early as 4 weeks 
compared to BCP alone. Histomorphometric assessment demonstrated accelerated bone formation prominent at 
the defect margins and surrounding individual BCP granules, with evidence of intramembranous ossification. 
These results highlight the capacity of SBP to be an effective regulator of osteoblastic function and may be 
beneficial as a new and cost effective osteo-inductive agent to accelerate repair of large bone defects.   
1. Introduction 
Large bone defects which occur as a result of trauma, tumor resection 
and fractures remain a significant problem in regenerative medicine. 
Autogenous bone graft transplantation is the current “gold standard” for 
the treatment of large bone defects due to their osteogenicity, osteo-
conductivity and osteoinductivity potential (Jimi et al., 2012; Helm 
et al., 2001). However, the amount of autologous bone which can be 
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harvested is limited and is associated with the potential for donor site 
morbidity at the second surgical site, resulting in higher complication 
rates and longer rehabilitation times (Almaiman et al., 2013; Finke-
meier, 2002; Gamradt and Lieberman, 2003; Homma et al., 2013). To 
address these limitations, biological alternatives such as allografts and 
xenografts have been developed, however these are suboptimal due to 
limited availability, high cost, immunogenicity and poor osteoinduc-
tivity (Betz, 2002). 
The use of synthetic bone graft substitutes, often in the form of cal-
cium phosphate ceramics is increasing, owing to their ability to elimi-
nate many of the issues associated with the use of autologous and 
autograft bone (Fillingham and Jacobs, 2016). Of these, synthetic ma-
terials comprised of β-tricalcium phosphate (β-TCP) and hydroxyapatite 
(HA), termed biphasic calcium phosphate (BCP) have been studied 
extensively (Bouler et al., 2017), as the composition of these minerals 
are comparable to normal bone tissue (Kivrak and Taş, 1998). Although 
these materials demonstrate high biocompatibility and osteoconductive 
properties (Gronthos et al., 2000; Wongwitwichot et al., 2010), new 
bone formation is often limited due to poor osteoinductive capabilities 
(Yuan et al., 2002). This limitation can be overcome with the incorpo-
ration of osteoinductive agents such as BMP-2 to accelerate osteogenesis 
(Szpalski et al., 2012). BMP-2 is currently the only approved osteoin-
ductive factor used as a bone graft substitute. However, with increasing 
clinical use a number of drawbacks to BMP-2 have emerged, including 
ectopic bone formation, osteoclast mediated bone resorption (Tannoury 
and An, 2014; James et al., 2016) and high dosage levels, raising con-
cerns about efficacy and cost effectiveness (Yaszemski et al., 1996). 
Therefore, there is an urgent need to identify new biological agents with 
osteoinductive capabilities that accelerate bone formation and remod-
elling without adverse effects. 
Peroxidases are a group of haem-containing enzymes found in ani-
mals, plants and micro-organisms (Hiraga et al., 2001). This family of 
enzymes share the same catalytic mechanism, and convert hydrogen 
peroxide and halide ions into hypohalous acid, which is one of the most 
reactive oxidants produced in vivo and is responsible for peroxidase anti- 
microbial actions (Aruoma and Halliwell, 1987). We have recently 
discovered new functional roles for peroxidase enzymes, including 
mammalian myeloperoxidase (MPO) and eosinophil peroxidase (EPO), 
plant-derived soybean peroxidase (SBP) and horseradish peroxidase 
(HRP). These roles include the ability to regulate fibroblast collagen 
extracellular matrix (ECM) biosynthesis (DeNichilo et al., 2015), drive 
angiogenesis (Panagopoulos et al., 2015) and inhibit osteoclastogenesis 
(Panagopoulos et al., 2017a). Collectively, these findings suggest that 
peroxidases may have an important role in tissue repair. In addition, we 
have recently reported new roles for mammalian peroxidases in bone 
repair, by their ability to promote osteoblast collagen biosynthesis, 
osteogenic gene expression and bone matrix mineralization (DeNichilo 
et al., 2016). SBP is highly biologically active and exceedingly stable at 
high temperatures and low pH (Henriksen et al., 2001). SBP is an 
attractive candidate to investigate in the context of bone repair due to 
low economical production costs and previous anectodal studies that 
have suggested consumption of soy products can elicit favourable effects 
on bone health and mineral density (Zhang et al., 2005; Shams-White 
et al., 2018). 
Herein, we report for the first time, that SBP has the ability to 
stimulate the release of collagen type I and promote matrix minerali-
zation by primary human osteoblasts. We also evaluated the osteoin-
ductive capacity of SBP, in combination with a commercially available 
BCP, to accelerate bone regeneration in critical size defects created in 
the long bones of sheep. 
2. Materials and methods 
2.1. Ethics statement 
Normal human bone tissue was obtained with informed written 
donor consent, and approved for use by the human ethics committee of 
the Royal Adelaide Hospital/University of Adelaide (Approval No. RAH 
090101). The use of sheep was approved by the Animal Ethics Com-
mittee of the University of Adelaide (M-2015-044A) and conducted at 
the Medical Engineering Research Facility, Chermside, QLD. 
2.2. Animals 
Four male castrated, wethers sheep aged 3–5 years, weighing 56–69 
kg (mean: 60; SD ± 5.9) were randomly assigned with even distribution, 
to receive the experimental treatment in either the left or right hind limb 
to eliminate bias. The opposing hind limb received the control 
treatment. 
2.3. Osteoblast cell culture 
Normal human bone-derived osteoblasts were isolated from inter-
trochanteric trabecular bone samples from three donors of both genders 
(1 male and 2 female), aged between 46 and 67 years, undergoing pri-
mary hip and knee replacement surgery, as described previously (Atkins 
et al., 2003). Human osteoblasts were culture expanded using Dulbecco's 
Modified Eagle's Medium (DMEM; high glucose with no ascorbic acid; 
AA), supplemented with 2 mmol/L glutamine, 100 IU/mL penicillin, 
100 μg/mL streptomycin, 20 mmol/L HEPES, and 10% foetal bovine 
serum (FBS; Invitrogen Life Technologies, Carlsbad, CA) in a 5% CO2- 
containing humidified atmosphere. These cells maintain an osteoblastic 
phenotype in culture and stained positive for alkaline phosphatase ac-
tivity (DeNichilo et al., 2016). 
2.4. Collagen I enzyme-linked immunosorbent assay (ELISA) 
To evaluate the effect of SBP on collagen I production, osteoblasts 
were cultured and treated as previously described (DeNichilo et al., 
2016). Briefly, osteoblasts were cultured in 96-well plates for 5 days in 
complete growth media until confluent. Cells were starved overnight in 
serum-free DMEM and then stimulated for an additional 72 h in serum- 
free DMEM containing either AA 2-phosphate at 100 μmol/L (Wako 
Chemical Industries, Osaka, Japan) as a positive control, or with 
increasing concentrations of SBP (Bio-Research Products, North Liberty, 
IA) in the absence of AA supplementation. Osteoblast basal-conditioned 
media was then collected for measurement of secreted, soluble type I 
collagen by ELISA. Cell viability was then assessed using the ala-
marBlue™ fluorescent dye assay (Invitrogen Life Technologies), ac-
cording to manufacturer's instructions. Fluorescence was measured at 
wavelengths of 530 nm excitation and 595 nm emission using a 
FLUOstar Optima plate reader (BMG Labtek Australia, Mornington, 
VIC). 
The quantity of soluble type I collagen in cell-conditioned medium 
was measured by a direct coat enzyme-linked immunosorbent assay 
method, as previously described (DeNichilo et al., 2016). Samples and 
standards were added to a 96-well Maxisorp plate (Nunc) and left at 4 ◦C 
overnight. The plate was then washed with phosphate-buffered saline 
(PBS) with 0.05% Tween, 2.5% bovine serum albumin (BSA)/PBS 
blocking solution added to each well and the plate incubated for 1 h at 
room temperature. The plate was then washed and primary antibody 
(0.25 μg/mL rabbit anti-human-collagen I polyclonal; Rockland Immu-
nochemicals, Limerick, PA) in 5% non-fat dairy milk added to each well 
for 3 h. After washing, europium-tagged anti-rabbit secondary antibody 
(0.5 μg/mL in 1% BSA/PBS; Perkin Elmer Life Sciences, Turku, Finland) 
was added and the plates incubated for 1 h at room temperature. After a 
final wash, Enhancement Solution (Perkin Elmer Life Sciences) was 
added, and time-resolved fluorescence was measured at excitation 355 
nm and emission 620 nm using a FLUOstar Optima plate reader (BMG 
Labtek Australia). The collagen content of each sample was determined 
from the standard curve (μg/mL), constructed from purified type I 
human placental collagen (BD Biosciences Australia, North Ryde, NSW) 
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and then normalised to DMEM-only treated cells. 
2.5. In vitro mineralization 
Normal human bone-derived osteoblasts were seeded into 96-well 
plates (Nunc) at a density of 1.2 × 104 cells per well and cultured for 
5 days in ascorbic acid-free (AA-free) 10% FBS/DMEM at 37 ◦C and 5% 
CO2. Triplicate wells were stimulated with SBP in osteogenic DMEM 
mineralization medium [DMEM supplemented with 5% FBS, 100 μmol/ 
L AA 2-phosphate (Wako Chemical Industries), 10− 8 mol/L dexameth-
asone (Hospira Australia, Mulgrave, VIC), and 10 mmol/L β-glycer-
ophosphate (Sigma-Aldrich)] to assist bone mineral formation. Cells 
were maintained in culture for 21 days, with fresh medium with or 
without SBP, changed every 7 days. To detect matrix mineralization, the 
Alizarin Red staining method was used as previously described (DeNi-
chilo et al., 2016). Briefly, cells were washed with PBS and fixed with 
10% buffered formalin. The fixed cells were then washed twice with 
distilled water and stained with 2% Alizarin Red S solution (Sigma- 
Aldrich). The stained mineralized matrix was photographed using a 
Nikon Eclipse 50i microscope attached to a DS-L2 control unit (Digital 
Sight, Nikon Europe, Amsterdam, The Netherlands) and a DS-Fi1 digital 
camera (Nikon Corporation, Tokyo, Japan). 
The extent of mineralization was quantitated by eluting the Alizarin 
Red S dye with 10% (w/v) cetylpyridinium chloride (Sigma-Aldrich) in 
10 mM phosphate buffer pH 7.0, for 10 mins to release remaining 
calcium-bound Alizarin Red S. Absorbance was measured at a wave-
length of 570 nm using a FLUOstar Optima plate reader (BMG Labtek 
Australia). 
2.6. Microarray 
A microarray was performed to evaluate the effects of SBP on pro- 
osteogenic gene expression in primary human osteoblasts. Briefly, os-
teoblasts harvested from a single donor were seeded at a density of 6 ×
104 into T25 culture flasks in 10%FBS/DMEM/ and maintained in cul-
ture for 5 days. On reaching confluence, cells were stimulated with or 
without 5 μg/mL SBP for 12 days in osteogenic DMEM mineralization 
medium. Total RNA was harvested using an RNeasy Mini Kit (Qiagen 
Australia, Chadstone, VIC) according to the manufacturer's instructions 
and used to probe the Illumina HT-12 microarray platform, targeting 
over 47,000 human transcripts (Australian Genome Research Facility, 
Parkville, VIC). The Illumina GenomeStudio software (Version 1.9.0) 
was used to extract and normalise the expression data for the mean in-
tensity of the array. Genes that were statistically significant (p = ≤0.05) 
and exceeded a pre-set threshold for significantly higher (≥1.5-fold 
change) or lower (≤1.5-fold change) expression compared to control 
were included for further analysis. Of the genes presented in the array, 
836 genes met this prerequisite. Only those genes which had the greatest 
difference in fold change previously implicated in osteogenesis and 
repair were selected for validation using RT-PCR analysis. Functional 
pathways were analysed using the open web-based Database for Anno-
tation, Visualisation and Integrated Discovery (DAVID) Bioinformatics 
Resources 6.7 (Da et al., 2009; Huang da et al., 2009) (Table 1). 
Microarray data (GSE168303) is available at https://www.ncbi.nlm.nih. 
gov/geo/query/acc.cgi?acc=GSE168303. 
2.7. Quantitative real-time PCR (qRT-PCR) 
To validate candidate osteogenic genes from the microarray, qRT- 
PCR was performed based on the above-mentioned conditions with 
SBP at 6.25 μg/mL. Custom TaqMan® Array Fast Plates (Thermo Fisher, 
Scoresby, VIC) were pre-spotted with TaqMan® Gene Expression Assay 
probes for BMP-2, BSP, WNT-5A, FRZ–B, CCL5, CXCL5, CXCL6, 
CXCL12, MMP1, MMP3, IL6 and IL8. GAPDH was used as the control 
house-keeping gene. Quantitative RT-PCR was performed using Taq-
Man® Fast Advanced Master Mix (Thermo Fisher, Scoresby, VIC), in a 
ViiA 7 Real-Time System (Applied Biosystems, Foster City, CA). 
2.8. In vivo sheep model and surgery 
The sheep (n = 4) were fasted for 12 h prior to surgery but had ad 
libitum access to water during this time. To alleviate post-operative pain, 
a fentanyl patch (2–3 μg/kg/h) was applied 24 h prior to surgery and 
reapplied every 72 h for a minimum of 10 days. After pre-emptive 
sedation and analgesia with midazolam (0.2 mg/kg) and buprenor-
phine (0.005 mg/kg), animals were anaesthetised with Propofol, which 
was administered until effect (3–4 mg/kg). Animals were then intubated 
and administered Isoflurane in oxygen at 2%. A patient warmer was 
used during the procedure to keep the animal's body temperature stable 
and to prevent hypothermia. The antibiotic, Cephalosporin (22 mg/kg) 
and anti-inflammatory, Meloxicam (0.2 mg/kg) were administered pre- 
emptively and during the surgical procedure. Non-steroidal anti-in-
flammatory flunixin meglumine (1.1 mg/kg) was also administered. 
Animals were positioned in dorsal recumbency and the operative site for 
each hind limb was prepared through sequential sterilising scrubs and 
draping. 
2.9. Femoral condyle implantation 
A veterinary surgeon marked and created a 2–3 cm incision, directly 
over the mid-medial aspect of the femoral condyle, revealing the un-
derlying soft tissue which was separated to expose the bone. A 12 mm 
diameter, 10 mm deep defect was then created with sequential use of 
differing size drill heads. This method was used to avoid unnecessary 
thermal necrosis. The defect was then flushed with saline to remove any 
remaining bone fragments. Once the defect was created, commercially 
available BCP [15% HA/85% β-TCP] granules (Medtronic Sofamor 
Danek, Memphis, TN) were prepared for treatments and deposited into 
the condyle defect. In one defect, 1.25 g BCP, which was pre-soaked for 
15 mins in 5 mL soybean peroxidase (650 μg/mL) was added. The other 
defect received 1.25 g BCP pre-soaked with 5 mL saline (Hartmann's 
solution, Baxter Healthcare, Coparoo, QLD) solution as the control. It is 
important to note that the total amount of SBP was fully absorbed into 
the BCP granules which were then gently compacted into the defect to 
ensure consistent and even distribution. The wound was closed using 0- 
vicryl in a cruciate pattern for the deep fascial layer and continuous 
pattern for the subcutaneous layer. Metallic skin staples were then 
applied over the surface. Finally, a bandage with antimicrobial dressing 
was applied over the surgical site. Animals remained in a sling for 24 h 
before being moved to indoor housing for the entirety of the study. The 
animals were sacrificed 4 weeks post-surgery and specimens were ob-
tained by aseptic technique. 
2.10. Microcomputed tomography (micro-CT) imaging 
Samples in 70% ethanol were cut to size in order to fit within a 36.9 
mm diameter sample tube with the drill hole defect in vertical 
Table 1 
Pathways of genes differentially expressed by SBP-treated osteoblasts.  
Term Count Genes Fold 
enrichment 
GO:0001503 ~ ossification  2 BSP, BMP2,  29.40 
GO:0006954 ~ 
inflammatory response  
5 IL6, BMP2, IL8, CXCL6, 
CCL5  
18.92 
GO:0006955 ~ immune 
response  
6 IL6, IL8, CXCL5, CXCL6, 
CXCL12, CCL5  
10.69 
GO:0009611 ~ response to 
wounding  
5 IL6, BMP2, IL8, CXCL6, 
CCL5  
11.60 
GO:0016477 ~ cell 
migration  
4 IL6, IL8, CXCL12, CCL5  17.82 
GO:0031012 ~ 
extracellular matrix  
3 WNT5A, MMP3, MMP1  12.34  
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orientation. The samples were scanned in a micro-CT scanner 40 (Scanco 
Medical, Bassersdorf, Switzerland) at an energy of 70 kV and intensity of 
114 μA with 200 μs integration time, resulting in an isotropic voxel size 
of 36 μm. The reconstructed scans were evaluated using Scanco μCT 
Evaluation Program (v6.5–3). A cylindrical volume of interest (VOI) 
with a diameter of 11 mm was defined for the analysis. The vertical 
evaluation length (cylinder height) was defined in a preview and con-
sisted of the central, cylindrical section of the defect (approximately 100 
slices or 3.6 mm), excluding the zones at the top and bottom ends of the 
defect to prevent “boundary effects.” To identify newly formed bone 
throughout the VOI, and to reduce partial volume effect at the grain 
boundaries of the ceramic granules, a masking procedure was employed 
(Burghardt et al., 2008). First, using a high threshold of 5069 Hounsfield 
Units (HU, 872.6 mg HA/mm3), with a gauss filter of σ = 0.8 and a 
support of 1.0 was applied to segment the BCP granules within the 
defect. Next, the granules were enlarged by 2 voxels on all faces, and this 
enlarged granule volume was deducted from the VOI, leaving only the 
intra-granule space of the VOI. Newly formed bone was segmented from 
this space with a lower threshold of 2121 HU (356.3 mg HA/mm3), a 
gauss filter of σ = 1.8 and a support of 3.0. For the quantitative evalu-
ation, the total cylindrical volume of interest (TV), the volume of the 
segmented newly formed bone (BV) and the average mineral density of 
the newly formed bone were calculated. 
2.11. Histology and histomorphometric analysis 
Femoral condyles were subjected to ethanol dehydration steps prior 
to being placed into a Methyl Methacrylate (MMA): Polyethylene Glycol 
400 (PEG) solution (100% MMA: 10% PEG). Femura were left in the 
MMA: PEG solution for 21 days, at which time polymerisation was 
induced using a solution containing MMA: PEG: Perkadox (0.2%). 
Trimmed resin blocks were sectioned in the sagittal plane at 10 μm 
thickness. Sections were prepared for Toluidine Blue (1% sodium tet-
raborax) and Tartrate Resistant Acid Phosphatase (TRAP) staining and 
counterstained with hematoxylin as previously described (Arthur et al., 
2013). The stains were visualised with the Olympus BX53F microscope 
and imaged using the Olympus DP74 camera. Two dimensional histo-
morphometric analysis of the femoral condyles were performed using 
OsteoMeasure™ software (OsteoMetrics, Decatur, USA) as previously 
described (Nguyen et al., 2016), where the assessor was blinded to the 
sample identity. 
2.12. Statistical analysis 
Data points derived from experiments are reported as the mean ±
standard error of the mean (SEM). Analysis of variance to determine the 
significant difference between samples was performed using the paired 
two-tailed Student's t-test on GraphPad Prism 8 Version 8.4.1 for Win-
dows (GraphPad Prism Software, San Diego, CA). 
3. Results 
3.1. SBP stimulates osteoblast collagen type I secretion 
Collagen type I is the most abundant protein in bone and accounts for 
approximately 90% of the organic matrix in bone (Feng, 2009). When 
stimulated with increasing concentrations of SBP, in the absence of AA 
for 72 h, primary human osteoblasts displayed a dose-responsive in-
crease in collagen type I release. Maximal doses of SBP resulted in a 
three-fold increase in soluble collagen type I release which was com-
parable to the amount measured in the presence of ascorbic acid (AA), 
which was used as the positive control (Fig. 1A). Notably, a significant 
increase in collagen type I secretion was observed at the lowest dose of 
SBP of 1.5 ng/mL. Assessment of cell viability indicated that SBP and AA 
had no impact on osteoblast numbers (Fig. 1B). This confirmed that SBP 
is non-toxic at the doses tested and importantly, shows the increase in 
collagen type I was not related to effects on cellular proliferation., These 
results demonstrate that the plant-derived SBP can promote collagen 
type I secretion by osteoblasts in an ascorbic acid-independent manner, 
consistent with previous studies of mammalian peroxidases (DeNichilo 
et al., 2016). 
3.2. SBP stimulates osteoblast matrix mineralization in vitro 
To determine whether SBP could also influence matrix mineraliza-
tion in vitro, primary human osteoblasts were cultured in increasing 
concentrations of SBP up to 12.5 μg/mL in the presence of DMEM 
Fig. 1. SBP promotes collagen I release by cultured human osteoblasts. (A) ELISA 
detection of soluble collagen I in osteoblast-conditioned medium after 72 h 
stimulation with SBP at the doses indicated. Ascorbic acid 2-phosphate (AA) at 
100 μmol/L served as the positive control, whereas cells treated with Dulbecco's 
modified Eagle's medium (DMEM) alone (unstim) served as the baseline con-
trol. The levels of collagen I are expressed as fold change and normalised to the 
unstim control. The data are pooled from three separate donors performed in 
triplicate. (B) Viability of cultured osteoblasts after 72 h stimulation as assessed 
using the alamarBlue dye assay. Cell viability was normalised, so the average 
values of unstim cells were set to 100% relative to each peroxidase dose. The 
data are pooled from three experiments each conducted using cells derived 
from three donors. Data are the mean ± SEM for unstim, AA, and each 
peroxidase dose. (†P < 0.01; ‡P < 0.001). 
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mineralization media for 21 days. Osteoblasts cultured with SBP pro-
duced more calcium deposits relative to vehicle control (Unstim) in a 
dose-dependent manner, based on Alizarin Red staining (Fig. 2A). 
Quantification of the eluted Alizarin Red S dye revealed that the stim-
ulation of SBP resulted in a significant increase in mineralization from 
1.6-fold at the lowest dose (0.78 μg/mL) up to 4-fold increase at the 
highest doses (from 3.25 to 12.5 μg/mL) compared to no SBP (Unstim) 
(Fig. 2B). Together, these data suggest that SBP promotes matrix 
mineralization of stimulated primary human osteoblasts. 
Furthermore, to investigate the capacity of SBP to perform as an 
osteoinductive agent in vivo, we evaluated human osteoblast migration 
and mineralization in a three-dimensional collagen scaffold presoaked 
with or without SBP. These supportive in vitro studies suggest that SBP 
stimulates osteoblast matrix infiltration after 14 days (Supp. Fig. 1A) 
and may enhance matrix mineralization after 28 days (Supp. Fig. 1B). 
3.3. SBP regulates expression of genes involved in osteoblast function 
Next, we sought to determine the changes in osteoblast gene 
expression mediated by SBP. To this end, we performed a RNA micro-
array on SBP-treated osteoblasts which identified 6554 genes that where 
differentially expressed, of which, 12 key genes involved in osteoblast 
function and regeneration were identified. Using web-based classifica-
tion programs (as described in the Methods), the differentially expressed 
genes were characterised into six categories: those involved in ossifi-
cation, inflammatory and immune responses, cell migration, extracel-
lular matrix and genes expressed in response to healing (Table 1). The 
qRT-PCR analysis confirmed the microarray gene expression profile for 
BMP-2, BSP, WNT-5A, FRZ–B, CCL5, CXCL5, CXCL6, CXCL12, MMP1, 
MMP3, IL-6 and IL-8 (Fig. 3). Taken together, these results suggest that 
peroxidases act by stimulating the differential regulation of effector 
genes that are key to osteogenesis and repair. 
3.4. SBP promotes bone regeneration of critical size defects in the long 
bones of sheep 
Ovine models have been used extensively to model human bone 
structure and bone metabolism and to investigate various osteoinductive 
factors (Field et al., 2011; Field et al., 2009). To demonstrate the efficacy 
of SBP-targeted fracture therapy, we used a SBP concentration of 650 
μg/mL delivered on BCP granules to treat a standardized bilateral 
femoral drill-hole defect (Supp. Fig. 2A). Saline and SBP-soaked BCP 
granules were prepared and implanted directly into the defect site 
(Supp. Fig. 2B). No surgical complications or postoperative morbidities 
were reported. Using micro-CT imaging and analysis, the effect of SBP in 
combination with BCP granules on bone formation after 4 weeks of 
implantation was evaluated. Representative three-dimensional re-
constructions of the micro-CT images encompassing the central zone of 
the defect (Fig. 4A) showed that SBP treatment increased bone forma-
tion compared to saline control (Fig. 4B). Quantitative analysis of the 
reconstructions revealed a statistically significant 2.7-fold increase in 
bone to tissue volume at the defect site in the SBP-treated limbs 
compared to saline control (Fig. 4C). 
Histological analysis of the defect sites was performed on sections 
stained with toluidine blue to identify new bone formation and osteo-
blasts, whereas TRAP staining was used to identify the osteoclast pop-
ulation (Fig. 5A–B). Two dimensional double-blinded 
histomorphometric assessment through the mid-region, relative to 
depth of the defect suggested that the presence of SBP promoted new 
bone formation when compared to control although, this did not reach 
statistical significance (p = 0.054) (Fig. 5C). This observation correlated 
with a decrease in the amount of granule area relative to tissue volume 
at the defect margins that was not due to changes in fibrous tissue vol-
ume. Furthermore, while not reaching statistical significance, SBP 
stimulated an associated increase in trabecular number and number of 
osteoblasts. TRAP staining of the defect site suggested that while SBP did 
not influence osteoclast formation, or number, osteoclasts were found to 
aggregate at the boundary between the granule and the newly miner-
alizing fibrous tissue. This is consistent with the bone remodelling 
process where osteoclasts are present and important during the resorp-
tion phase, remodelling the injury site and mostly devoid during the 
reversal stage, which prepares for a permissive bone forming environ-
ment. Collectively this data supports the in vitro and micro-CT three 
dimensional findings that SBP enhances bone formation and potentially 
promotes/supports infiltration of osteogenic precursors into the defect 
area. 
4. Discussion 
Bone repair following injury or disease is a highly coordinated and 
complex process that involves the interplay of numerous cell types, and 
their extracellular matrix components. Recruited to the injury site from 
the surrounding tissue, osteoblasts have central role for the synthesis 
and deposition of a collagen-rich extracellular matrix (ECM) that sub-
sequently mineralizes to form bone. Circulating inflammatory cells, 
including neutrophils, eosinophils and macrophages, infiltrate the 
fracture site during the early inflammatory phase of this bone healing 
process (Andrew et al., 1994; Claes et al., 2012; Prasad and Udupa, 
1972), where they release pro-osteogenic factors locally that influence 
osteoblast recruitment, functionality and the regenerative process. 
Peroxidases are heme-containing enzymes are also released in abun-
dance at sites of injury and inflammation by the infiltrating immune 
cells and, until recently, their functional role was thought to be limited 
to providing oxidative defence against invading bacteria and other 
Fig. 2. SBP promotes osteoblast matrix mineralization in vitro. (A) Representative 
images of Alizarin Red stained cultured human osteoblasts stimulated with SBP 
for 21 days at the various doses indicated. (B) Quantitation of mineralized 
calcium extracted from cultured osteoblast monolayers following stimulation 
with SBP for 21 days at the doses indicated. Cells treated with mineralization 
medium alone (unstim.) served as the baseline control. The levels of mineral-
ized calcium are normalised to the unstim control and expressed as fold change. 
Statistical significance was calculated by two-tailed Student's t-test with the 
various doses of SBP compared to the mineralization medium alone (unstim) 
group. Data are the mean ± SEM of three independent donors. (‡P < 0.001). 
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pathogenic microorganisms. However, we have recently uncovered 
prominent and previously unrecognised roles for this group of enzymes 
in bone biology that has great potential as a therapy for bone repair. Our 
previous studies revealed that mammalian peroxidases, including MPO 
and EPO, as well as plant derived peroxidase proteins, such as HRP and 
SBP, regulate fibroblast collagen extracellular matrix biosynthesis 
(DeNichilo et al., 2015), regulate collagen biosynthesis and matrix 
mineralization by human osteoblasts (DeNichilo et al., 2016), inhibit 
osteoclast differentiation and bone resorption (Panagopoulos et al., 
2017b) and drive angiogenesis (Panagopoulos et al., 2015). These bio-
logical processes are intimately involved in the pathway to bone repair. 
Until now the use of a peroxidase enzyme to therapeutically promote 
bone regeneration in vivo has never been contemplated or demonstrated. 
In the present study, we investigated the effect of the plant-derived SBP 
in regulating bone matrix formation in vitro and bone ossification in vivo 
as a potential osteoinductive agent. 
Collagen type I is the major extracellular matrix constituent of bone 
and its synthesis by osteoblasts is critical for normal bone formation 
(Cox et al., 2010). We report here for the first time, that SBP stimulates 
collagen I release by human osteoblasts in the absence of AA supple-
mentation akin to its mammalian family of peroxidase enzymes, MPO 
and EPO (DeNichilo et al., 2015). However, unlike MPO and EPO, SBP 
was found to be more potent at inducing a collagen response at much 
lower concentrations, indicative of its greater enzymatic catalytic ac-
tivity (DeNichilo et al., 2015). The role of AA in ECM production has 
been well characterised, by its ability to promote hydroxylation of 
peptidyl-proline which results in the assembly of a stabilised triple- 
helical procollagen molecule, subsequently leading to a collagen-rich 
matrix that is able to become mineralized (Franceschi and Iyer, 1992). 
In addition to stimulating an increase in collagen type I, we demonstrate 
that increasing concentrations of SBP, significantly increased the 
mineralization rate when compared to AA alone. Bone matrix mineral-
ization is the final stage of ossification leading to the formation of new 
bone. These results suggest that the composition of the collagen fibrils 
induced by SBP are indeed appropriate to ensue mineral accumulation, 
while also enhancing the bone mineralization process when cultured in 
osteogenic media. The interaction between osteoblasts and organic 
matrix components plays a critical role on cell differentiation, survival, 
proliferation, and matrix mineralization (Feng, 2009). In this regard, we 
show in vitro that after two weeks of culture, SBP promotes osteoblast 
infiltration into a collagen-rich three-dimensional scaffold (INTEGRA®) 
and a concomitant increase in matrix mineralization after just four 
Fig. 3. SBP regulates osteogenic gene expression. Quantitative real-time PCR analysis of the BMP-2, WNT-5A, BSP, FRZ–B, CCL6, CXCl12, IL-6, and MMP1 mRNA 
expression (normalised to GAPDH) in cultured osteoblasts following stimulation with 6.25 μg/mL soybean peroxidase (SBP) for 12 days. Cells treated with DMEM 
mineralization medium (unstim) served as the baseline control. Transcript levels were normalised to and expressed as fold change relative to the unstim control. 
Statistical significance was calculated by two-tailed Student's t-test with the SBP treatment group compared to unstim. Data are the mean ± SD of triplicate de-
terminations. (†P < 0.01; ‡P < 0.001). 
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weeks. These studies provided important information to explore the 
effects of SBP on bone formation in vivo. 
Mechanistically, our analysis of global gene expression shows that 
SBP is an effective regulator of several well-characterised genes known 
to be involved in osteoblast functions including, differentiation, 
mineralization and repair. However, an important limitation of this 
preliminary finding is that only one biological replicate was analysed. 
Using qRT-PCR validation we showed that SBP significantly up- 
regulated BMP-2, BSP and WNT-5A osteogenic signature genes. BMP-2 
is an important regulator in osteogenesis and it has been shown to 
drive BSP and WNT-5A expression by cultured osteoblasts (Lecanda 
et al., 1997; Robubi et al., 2014). Conversely, SBP down-regulates a 
known repressor of osteogenesis, FRZ-B related protein. FRZ-B acts as a 
competitive inhibitor of the WNT signalling pathway (Cho et al., 2008) 
which, like BMP-2 is a key modulator of bone formation (Takada et al., 
2009). These data suggest that SBP may, in part, promote intra-
membranous ossification via induction of BMP-2, which acts as an in-
termediate for the regulation of downstream effector genes. BMP-2 has 
been extensively tested both in vitro and in vivo as an agent for the repair 
of osseous defects both alone and in combination with other growth 
factors and biomaterials (Nakamura et al., 2005; Simmons et al., 2004; 
Street et al., 2002). While BMP-2 appears to be the most potent 
osteoinductive agent identified to-date, several studies have shown 
osteoclastic activation and bone resorption in response to BMP-2 treat-
ment (Seeherman et al., 2010; Toth et al., 2009), which may interfere 
with accelerated bone repair, supporting the notion that other biological 
factors are urgently required. 
In addition to the regulation of genes involved in osteoblast function 
by SBP, we observed significant up-regulation of numerous cytokines 
and chemokines including CCL5, IL-6, and CXCL12, which are crucial in 
the recruitment and regulation of bone remodelling. For example, CCL5 
is suggested to play a crucial role in osteoblast migration and survival in 
vitro (Yu et al., 2004), while in a knockout mouse model, bone formation 
was significantly impaired with an observed increase in osteoclasto-
genesis (Wintges et al., 2013). The pro-inflammatory cytokine IL-6 has 
been shown to enhance and inhibit osteoclastogenesis and more recently 
reported to be involved in promoting osteoclastogenesis by indirectly 
increasing RANKL expression by osteoblasts (Duplomb et al., 2008; 
Udagawa et al., 1995). Up-regulated CXCL12 is also involved in bone 
formation and healing. Previous studies have shown that blocking 
CXCL12 or its receptor CXCR4, led to reduced expression/function? of 
osteoblastic transcription factors and differentiation markers (Zhu et al., 
2007). Furthermore, in a mouse model, inactivation of CXCR4 resulted 
in reduced bone mass, decreased bone mineral density and decreased 
Fig. 4. Localised application of SBP-soaked BCP granules within a femoral defect increases bone formation. (A) Representative micro-CT image of reconstructed defect 
block used for quantification. A cylindrical volume of interest (VOI) with a diameter of 11 mm and length of 3.6 mm. (B) Representative micro-CT reconstructions of 
the defect site 28 days post-transplantation. (C) Quantitative analysis of the mean bone volume (BV) to tissue volume (TV) of the SBP treatment compared to BCP +
saline control within the defect site. Data was analysed and reported as the mean ± SEM. Analysis of variance to determine significant difference between samples 
was performed using the paired Student's t-test of four sheep for control and peroxidases. (*P < 0.05). 
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expression of collagen type I (Zhu et al., 2011). 
The ability of SBP to influence the mineralization process beyond the 
initial stage of collagen biosynthesis and the regulation of key osteo-
genic genes suggests that SBP possesses the necessary properties to 
induce osteogenic repair. To test this hypothesis, we utilised the critical- 
sized bone defect (CSD) model in sheep in combination with BCP serving 
as a scaffold, which is the ‘gold standard’ approach in evaluating new 
treatment modalities for bone repair or regeneration with similar bone 
metabolism to humans (Apelt et al., 2004; Theiss et al., 2005; Patel et al., 
2005). This hypothesis is further supported by our previous findings 
whereby SBP was found to induce connective tissue regeneration and 
intergration of a three-dimensional dermal regeneration scaffold in a 
Fig. 5. Histomorphometric analysis suggests SBP treatment enhances bone formation in a in vivo bone defect model. (A–B) Representative (A) toluidine blue and (B) TRAP 
stained sections of the sheep femoral defect treated with saline (MG + saline) or SBP-soaked (MG + SBP) HA/β-TCP Mastergraft® (MG) BCP granulesafter 28 days. 
(C) Histomorphometric analysis of the defect site represented as the (i) percentage of tissue volume to bone volume, (ii) percentage of granular area, (iii) percentage 
of fibrous tissue volume relative to tissue volume, (iv) trabecular number, and (v) number of osteoblasts. All statistical analysis was performed by a paired Student t- 
test, n = 3 animals. (Yellow asterisks = bone formation adjacent to BCP granules. “G” = location of MG granules. Red arrows = osteoblasts (dark blue) lining the new 
bone forming surface. Black arrows = embedded osteocytes (dark blue/ pale purple). Arrow heads = osteoclasts. Scale bar A-B = 50 μm). Statistical significance was 
calculated by two-tailed Student's t-test with the SBP treatment group compared to unstim. Data are the mean ± SD of triplicate determinations. 
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porcine full-thickness wound model (DeNichilo et al., 2015). The 
critical-sized femoral condyle defect model described herein, showed 
new bone formation and integration after 4 weeks of BCP implantation. 
Notably, the SBP soaked BCP implant significantly increased bone 
regeneration by 2-fold when compared to BCP alone as shown by micro- 
CT. Our blinded histomorphometry analysis of the tissue specimens 
validate the observed micro-CT results. In the SBP group, increased bone 
volume accounted for approximately 21% of the defect area, while in 
vehicle group the bone volume level was 12% which was almost a 2-fold 
difference. In addition to the increase in trabecular volume, it is evident 
that the presence of SBP promoted an increase in osteoblast infiltration 
and an overall increase in bone area. However, at the single 4 week time 
point, we observed no difference in the vessel (data not shown) or 
osteoclast number in either group, contrary to our previous findings 
showing peroxidase mediated increase in vascularisation and inhibition 
of osteoclastogenesis (Panagopoulos et al., 2015; Panagopoulos et al., 
2017a). Taken together, this study has demonstrated an ability for SBP 
to promote new bone formation without any apparent toxicity to the 
local cell population, where we see an abundance of osteoblasts and 
osteocytes, necessary for normal bone healing. 
In conclusion, our findings demonstrate for the first time, a pro- 
osteogenic role for SBP, by its ability to promote collagen I biosyn-
thesis and matrix mineralization and shows promising potential as a new 
and cost-effective therapeutic able to promote bone repair in vivo. 
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